Business Description
Janux Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US47103J1051
Share Class Description:
JANX: Ordinary SharesDescription
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.02 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.35 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 41.95 | |||||
| Beneish M-Score | -2.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -45.3 | |||||
| 3-Year EPS without NRI Growth Rate | -34.4 | |||||
| 3-Year FCF Growth Rate | -50.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -99.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.74 | |||||
| 9-Day RSI | 65.98 | |||||
| 14-Day RSI | 66.69 | |||||
| 6-1 Month Momentum % | 422.34 | |||||
| 12-1 Month Momentum % | 152.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 26.8 | |||||
| Quick Ratio | 26.8 | |||||
| Cash Ratio | 26.4 | |||||
| Days Sales Outstanding | 28.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5 | |||||
| Shareholder Yield % | -0.27 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -902.87 | |||||
| Net Margin % | -721.18 | |||||
| FCF Margin % | -648.58 | |||||
| ROE % | -17.94 | |||||
| ROA % | -15.96 | |||||
| ROIC % | -185.06 | |||||
| ROC (Joel Greenblatt) % | -253.73 | |||||
| ROCE % | -20.88 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 267.35 | |||||
| PB Ratio | 6.54 | |||||
| Price-to-Tangible-Book | 6.54 | |||||
| EV-to-EBIT | -30.2 | |||||
| EV-to-EBITDA | -31.03 | |||||
| EV-to-Revenue | 272.68 | |||||
| EV-to-Forward-Revenue | 695.08 | |||||
| EV-to-FCF | -42.04 | |||||
| Price-to-Net-Current-Asset-Value | 7.19 | |||||
| Price-to-Net-Cash | 7.31 | |||||
| Earnings Yield (Greenblatt) % | -3.31 | |||||
| FCF Yield % | -2.08 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:JANX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Janux Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8.083 | ||
| EPS (TTM) ($) | -1.33 | ||
| Beta | 0 | ||
| Volatility % | 474.73 | ||
| 14-Day RSI | 66.69 | ||
| 14-Day ATR ($) | 3.863123 | ||
| 20-Day SMA ($) | 41.7845 | ||
| 12-1 Month Momentum % | 152.67 | ||
| 52-Week Range ($) | 5.65 - 58.6936 | ||
| Shares Outstanding (Mil) | 51.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Janux Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Janux Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Janux Therapeutics Inc Frequently Asked Questions
What is Janux Therapeutics Inc(JANX)'s stock price today?
The current price of JANX is $48.69. The 52 week high of JANX is $58.69 and 52 week low is $5.65.
When is next earnings date of Janux Therapeutics Inc(JANX)?
The next earnings date of Janux Therapeutics Inc(JANX) is 2024-05-09 Est..
Does Janux Therapeutics Inc(JANX) pay dividends? If so, how much?
Janux Therapeutics Inc(JANX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers